OraSure Technologies (NASDAQ:OSUR) Lowered to "Sell" Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded OraSure Technologies from “Hold” to “Sell,” while Weiss Ratings also maintained a sell-level assessment. Analysts’ average rating is “Reduce,” with a $3.00 price target.
• OraSure shares opened at $4.05, up 2.0%, with a market capitalization of approximately $278.8 million. The stock has traded between $2.08 and $4.58 over the past 52 weeks.
• Insider and institutional activity was mixed but included a director’s purchase of 25,000 shares, while institutional investors own a substantial 93.5% of the company.

OraSure Technologies (NASDAQ:OSUR - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Sunday.

Separately, Weiss Ratings upgraded OraSure Technologies from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, June 4th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Reduce" and an average price target of $3.00.

OraSure Technologies Stock Up 2.0%

Shares of OraSure Technologies stock opened at $4.05 on Friday. OraSure Technologies has a 52-week low of $2.08 and a 52-week high of $4.58. The firm has a market cap of $278.84 million, a price-to-earnings ratio of -3.89 and a beta of 1.01. The company's 50-day simple moving average is $4.15 and its 200-day simple moving average is $3.38.

Insider Transactions at OraSure Technologies

In other OraSure Technologies news, Director Steven Kyle Boyd bought 25,000 shares of the stock in a transaction on Thursday, May 14th. The shares were purchased at an average cost of $2.99 per share, with a total value of $74,750.00. Following the completion of the transaction, the director directly owned 113,462 shares of the company's stock, valued at $339,251.38. This represents a 28.26% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.70% of the company's stock.

Institutional Trading of OraSure Technologies

Large investors have recently made changes to their positions in the stock. Amundi bought a new stake in shares of OraSure Technologies in the first quarter valued at approximately $47,000. AQR Capital Management LLC lifted its stake in shares of OraSure Technologies by 48.3% in the first quarter. AQR Capital Management LLC now owns 1,041,875 shares of the medical instruments supplier's stock valued at $3,511,000 after buying an additional 339,493 shares during the period. NewEdge Advisors LLC grew its position in OraSure Technologies by 32,595.9% during the first quarter. NewEdge Advisors LLC now owns 47,736 shares of the medical instruments supplier's stock worth $161,000 after buying an additional 47,590 shares in the last quarter. Empowered Funds LLC increased its stake in OraSure Technologies by 7.2% during the first quarter. Empowered Funds LLC now owns 405,216 shares of the medical instruments supplier's stock valued at $1,366,000 after acquiring an additional 27,310 shares during the period. Finally, Envestnet Asset Management Inc. increased its stake in OraSure Technologies by 32.7% during the second quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier's stock valued at $99,000 after acquiring an additional 8,133 shares during the period. Institutional investors own 93.50% of the company's stock.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company's flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.